Hodgkin’s disease refractory – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:00 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hodgkin’s disease refractory – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Ruxolitinib with Brentuximab or Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma https://clinicaltrials.eu/trial/study-of-ruxolitinib-with-brentuximab-or-pembrolizumab-for-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma/ Wed, 29 Apr 2026 15:03:44 +0000 https://clinicaltrials.eu/trial/study-of-ruxolitinib-with-brentuximab-or-pembrolizumab-for-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma/ This clinical trial is focused on studying a type of cancer called classical Hodgkin lymphoma (cHL), which is a cancer of the lymphatic system. The study is specifically for patients whose cHL has returned or did not respond to previous treatments. The trial is testing the effectiveness of combining a medication called ruxolitinib with either brentuximab vedotin or pembrolizumab. Ruxolitinib is a drug that helps to block certain proteins that can cause cancer cells to grow. Brentuximab vedotin is a type of medication known as an antibody-drug conjugate, which targets cancer cells, and pembrolizumab is an immunotherapy drug that helps the immune system fight cancer.

The purpose of the study is to see how well these drug combinations work in treating patients with relapsed or refractory cHL. The study is divided into two groups, or cohorts. In one group, patients will receive ruxolitinib with brentuximab vedotin, and in the other group, patients will receive ruxolitinib with pembrolizumab. The study will monitor the patients’ response to these treatments over a period of time, looking for signs of complete response, which means the cancer has disappeared, or partial response, where the cancer has shrunk but not completely gone away.

Throughout the study, researchers will also keep track of any side effects that occur and how they relate to the study drugs. The study aims to improve the rate of complete response compared to past treatments. Additionally, the study will explore the possibility of using these treatments to prepare patients for stem cell transplants, which can be a part of cancer treatment. The trial will also look for potential markers in the body that might predict how well a patient will respond to the treatment. The study is expected to continue until 2026.

]]> Study of Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma or Primary Mediastinal Large B-cell Lymphoma https://clinicaltrials.eu/trial/study-of-pembrolizumab-for-patients-with-relapsed-or-refractory-classical-hodgkins-lymphoma-or-primary-mediastinal-large-b-cell-lymphoma/ Wed, 29 Apr 2026 15:01:45 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-for-patients-with-relapsed-or-refractory-classical-hodgkins-lymphoma-or-primary-mediastinal-large-b-cell-lymphoma/ This clinical trial is focused on studying two types of blood cancers: Relapsed or Refractory Classical Hodgkin’s Lymphoma and Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma. These are conditions where the cancer has returned or has not responded to previous treatments. The treatment being tested in this study is a medication called Pembrolizumab, also known by its code name MK-3475. Pembrolizumab is given as an infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of the study is to evaluate how well Pembrolizumab works in treating these specific types of lymphoma. Participants in the study will receive Pembrolizumab every six weeks. The study will monitor the response of the cancer to the treatment, as well as any side effects that may occur. The study aims to gather information on how effective Pembrolizumab is in shrinking or controlling the cancer.

Throughout the study, participants will undergo regular check-ups and tests to assess their health and the progress of the treatment. The study will continue for a period of time to ensure that enough data is collected to understand the effects of Pembrolizumab on these types of lymphoma. The results will help determine if Pembrolizumab can be a beneficial treatment option for patients with these conditions.

]]> Study of Nivolumab and Chemotherapy Combination for Patients with Refractory Hodgkin’s Lymphoma https://clinicaltrials.eu/trial/study-of-nivolumab-and-chemotherapy-combination-for-patients-with-refractory-hodgkins-lymphoma/ Wed, 29 Apr 2026 14:58:12 +0000 https://clinicaltrials.eu/trial/study-of-nivolumab-and-chemotherapy-combination-for-patients-with-refractory-hodgkins-lymphoma/ This clinical trial is focused on studying a type of cancer called Hodgkin’s lymphoma, specifically in patients whose disease has not responded to initial treatment. The study will use a medication called nivolumab, which is given through an infusion into a vein. Nivolumab is a type of treatment that helps the immune system fight cancer cells. After receiving nivolumab, patients will undergo chemotherapy with three drugs: bendamustine, gemcitabine, and dexamethasone. This will be followed by a procedure called autologous bone marrow transplantation, where a patient’s own stem cells are used to help restore their bone marrow.

The purpose of this study is to evaluate how effective and safe this treatment approach is for patients with Hodgkin’s lymphoma that is resistant to previous treatments. The study will also look at the potential of using a blood test to predict how well patients might respond to the treatment. This blood test measures the amount of DNA from Hodgkin’s lymphoma cells circulating in the blood before the bone marrow transplantation.

Participants in the study will first receive nivolumab, followed by two cycles of the chemotherapy combination. Afterward, they will undergo the bone marrow transplantation. The study will monitor the patients to see how well the treatment works and to check for any side effects. The goal is to find out if this treatment can help patients achieve remission, which means the cancer is no longer detectable, and to understand how long patients can live without the disease getting worse.

]]>